Compare ACRS & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACRS | BYND |
|---|---|---|
| Founded | 2012 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Packaged Foods |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.0M | 269.7M |
| IPO Year | 2015 | 2018 |
| Metric | ACRS | BYND |
|---|---|---|
| Price | $4.59 | $0.82 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 7 |
| Target Price | ★ $10.20 | $0.83 |
| AVG Volume (30 Days) | 1.1M | ★ 49.4M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.01 | 24.69 |
| EPS | N/A | ★ N/A |
| Revenue | $1,683,000.00 | ★ $275,496,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.24 | $1.36 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.34 | $0.50 |
| 52 Week High | $5.15 | $7.69 |
| Indicator | ACRS | BYND |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 51.36 |
| Support Level | $4.15 | $0.81 |
| Resistance Level | $4.89 | $1.09 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 37.50 | 58.92 |
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.